Sarepta Therapeutics | SRPT - Sales Revenues

Stock Price
22.82
Daily Change
-0.41 -1.77%
Monthly
29.37%
Yearly
-56.45%
Q2 Forecast
22.53

Sarepta Therapeutics reported $442.9M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Moderna USD 678M 342M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025